Publications in collaboration with researchers from University Hospital of Würzburg (3)

2025

  1. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

    The Lancet Haematology, Vol. 12, Núm. 4, pp. e269-e281

2020

  1. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Blood Cancer Journal, Vol. 10, Núm. 9

2015

  1. Elotuzumab therapy for relapsed or refractory multiple myeloma

    New England Journal of Medicine, Vol. 373, Núm. 7, pp. 621-631